Modified-release hydrocortisone (Efmody®) in children with congenital adrenal hyperplasia: a retrospective registry study - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy and Safety of Modified-Release Hydrocortisone (Efmody®) in Pediatric Patients with Congenital Adrenal Hyperplasia: A Retrospective Analysis from a Registry

  • By

  • Erwin Lankes

  • Levin Wiebelt

  • Kathrin Bettina Helge

  • Dirk Schnabel

  • Peter Kühnen

  • Oliver Blankenstein

  • Uta Neumann

  • July 7, 2026

Share

Original Source(s)

Modified-release hydrocortisone (Efmody®) in children with congenital adrenal hyperplasia: a retrospective registry study

  • by Erwin Lankes, Levin Wiebelt, Kathrin Bettina Helge, Dirk Schnabel, Peter Kühnen, Oliver Blankenstein, Uta Neumann

  • July 7, 2026

Related Content

Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis

Challenges in diagnosis of reninoma: three case reports and literature review

Sex, Gender and Gender Identity: A Case for Conceptual Clarity